Status:
NOT_YET_RECRUITING
A New Blood Score for Myelofibrosis Staging
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Myeloproliferative Neoplasm
Eligibility:
All Genders
18-100 years
Brief Summary
BCR:ABL1 negative myeloproliferative neoplasms (MPN) include three entities: polycythemia vera, essential thrombocythemia and primitive myelofibrosis. Myelofibrosis is a life-threatening complication ...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Diagnosis of BCR::ABL1 negative MPN according to WHO criteria classification
- Indication for bone marrow biopsy
- Non opposition
- Social security affiliation
Exclusion
- Non-contributory biopsy
- AML transformation
- Organ fibrosis (liver, lung, kidney…)
- HSCT
- Chronic inflammatory disease
Key Trial Info
Start Date :
February 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06177366
Start Date
February 1 2024
End Date
February 1 2026
Last Update
December 20 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.